Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease

We examined the impact of disease duration on clinical outcomes and safety in a post hoc analysis of a remission maintenance trial with adalimumab in patients with moderate to severe CD. Patients in the CHARM trial were divided into 3 disease duration categories:

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Crohn's and colitis 2013-04, Vol.7 (3), p.213-221
Hauptverfasser:	Schreiber, S, Reinisch, W, Colombel, J F, Sandborn, W J, Hommes, D W, Robinson, A M, Huang, B, Lomax, K G, Pollack, P F
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Adolescent Adult Aged Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Crohn Disease - drug therapy Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Humans Induction Chemotherapy Kaplan-Meier Estimate Logistic Models Maintenance Chemotherapy Male Middle Aged Severity of Illness Index Time Factors Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We examined the impact of disease duration on clinical outcomes and safety in a post hoc analysis of a remission maintenance trial with adalimumab in patients with moderate to severe CD. Patients in the CHARM trial were divided into 3 disease duration categories:
ISSN:	1876-4479
DOI:	10.1016/j.crohns.2012.05.015